Genetic and Epigenetic Features of Rapidly Progressing IDH-Mutant Astrocytomas.

Authors:
Gaoxiang Jia, MS
Gaoxiang Jia, MS
Southern Methodist University
Graduate Student
Biostatistics
Dallas, Texas | US
Adwait Sathe, PhD
Adwait Sathe, PhD
The University of Texas at Southwestern Medical Center
Computational Biologist
Dallas, Texas | United States
Adwait Amod Sathe, PhD
Adwait Amod Sathe, PhD
UT Southwestern Medical Center
Computational Biologist
Dallas, TX | United States

J Neuropathol Exp Neurol 2018 07;77(7):542-548

Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas.

IDH-mutant astrocytomas are significantly less aggressive than their IDH-wildtype counterparts. We analyzed The Cancer Genome Atlas dataset (TCGA) and identified a small group of IDH-mutant, WHO grade II-III astrocytomas (n = 14) with an unexpectedly poor prognosis characterized by a rapid progression to glioblastoma and death within 3 years of the initial diagnosis. Compared with IDH-mutant tumors with the typical, extended progression-free survival in a control group of age-similar patients, the tumors in the rapidly progressing group were characterized by a markedly increased level of overall copy number alterations ([CNA]; p = 0.006). In contrast, the mutation load was similar, as was the methylation pattern, being consistent with IDH-mutant astrocytoma. Two of the gliomas (14%) in the rapidly progressing, IDH-mutant group but none of the other grade II-III gliomas in the TCGA (n = 283) had pathogenic mutations in genes (FANCB and APC) associated with maintaining chromosomal stability. These results suggest that chromosomal instability can negate the beneficial effect of IDH mutations in WHO II-III astrocytomas. The mechanism of the increased CNA is unknown but in some cases appears to be due to mutations in genes with a role in chromosomal stability. Increased CNA could serve as a biomarker for tumors at risk for rapid progression.

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnen/nly026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005148PMC
July 2018
63 Reads
3.800 Impact Factor

Publication Analysis

Top Keywords

rapidly progressing
12
progressing idh-mutant
8
mutations genes
8
chromosomal stability
8
rapid progression
8
increased cna
8
idh-mutant astrocytomas
8
ii-iii astrocytomas
8
grade ii-iii
8
idh-mutant
6
14% rapidly
4
contrast mutation
4
[cna] p = 0006
4
mutation load
4
p = 0006 contrast
4
methylation pattern
4
gliomas 14%
4
astrocytoma gliomas
4
alterations [cna]
4
consistent idh-mutant
4

References

(Supplied by CrossRef)
The 2016 World Health Organization classification of tumors of the central nervous system: A summary
Louis et al.
Acta Neuropathol 2016
CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2005–2009
Dolecek et al.
Neuro Oncol 2012
CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006–2010
Ostrom et al.
Neuro Oncol 2013
Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas
Sanson et al.
J Clin Oncol 2009
Mutant metabolic enzymes are at the origin of gliomas
Yan et al.
Cancer Res 2009
IDH1 and IDH2 mutations in gliomas
Yan et al.
N Engl J Med 2009
Biomarker-driven diagnosis of diffuse gliomas
Appin et al.
Mol Aspects Med 2015
Molecular pathways in gliomagenesis and their relevance to neuropathologic diagnosis
Appin et al.
Adv Anat Pathol 2015
Diffuse low-grade glioma: A review on the new molecular classification, natural history and current management strategies
Delgado-Lopez et al.
Clin Transl Oncol 2017
Mutational burden, immune checkpoint expression, and mismatch repair in glioma: Implications for immune checkpoint immunotherapy
Hodges et al.
Neuro Oncol 2017
Diagnostic and therapeutic biomarkers in glioblastoma: Current status and future perspectives
Szopa et al.
Biomed Res Int 2017

Similar Publications